Latest Blogs

Dec 03, 2019
ASCO's delegation to the AMA HOD invites all ASCO members to share their thoughts and concerns concerning issues affecting the practice of oncology, as your input directly impacts the delegation's work.
Dec 03, 2019
When a patient is looking for the word "cure," anything else, especially if vague, is not enough. "No evidence of disease" leaves room for doubt but, importantly, also room for hope.
Dec 02, 2019
Dr. Omid Etemadi describes the evolution of integrated cancer care in the Philippines. 
Nov 26, 2019
What does the future of immuno-oncology look like? Dr. Elizabeth A. Mittendorf invites you to be part of the conversation at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium in February.
Subscribe to this column

L. Michael Glode, MD, FACP, FASCO

L. Michael Glodé, MD, FACP, FASCO, is a Professor Emeritus at the University of Colorado Cancer Center. He previously served as Chair of ASCO's Integrated Media and Technology and Cancer Education Committees. He is the author of prost8blog, a blog to help patients and their families understand various aspects of prostate cancer.

Sep 09, 2019
A recent study on the risk of Alzheimer's disease or dementia following the use of ADT was disturbing to me on two levels.
Jul 02, 2019
Regardless of prognosis, we all must live with the reality that time is fleeting, and none of us have unlimited tomorrows.
Aug 31, 2018
Some reflections on John McCain, mortality, Hamilton, and the story you leave behind. 
Dec 21, 2016
I cannot count the number of times I have thought to myself, “If it were not for the PSA, you would no doubt be out there playing golf, skiing, biking, taking a grandchild to the park, or just enjoying life.” Living from one PSA to the next is a bad way to mark the passing of time.
Aug 08, 2016
For prostate cancer, there are both challenges and some early positive results from immunotherapy trials that remain intriguing. One of the key challenges is identifying those patients who will benefit from the treatment.
Jun 05, 2016
Much of the news this week in prostate cancer will be generated by the ASCO Annual Meeting in Chicago. There are likely to be considerable news releases regarding precision medicine, and especially AR-V7, so I thought I would explain this a bit.

Pages